Mobile

Immunogenicity, safety and reactogenicity study of GSK Biologicals’ pneumococcal vaccine (Synflorix™) when administered to children who are at an increased risk of pneumococcal infection

Mise à jour : Il y a 4 ans
Référence : EUCTR2011-006013-34

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To assess the immunogenicity of GSK Biologicals’ 10Pn-PD-DiT vaccine when administered to at-risk children aged between 2-17 years, either as a 2-dose catch-up vaccination in unprimed children or as a single dose in primed children.

Critère d'inclusion

  • Active immunization against disease caused by Streptococcus pneumoniae in children 2-17 years of age who are at increased risk of pneumococcal infection

Liens